Israel-based Stratasys – a 3D printing manufacturer, and CollPlant – a regenerative and aesthetic medicine company, announced a joint development of plant-based technologies for tissue regeneration and organ manufacturing.
Other stories:
The initial project of the Rehovot-based companies is to produce breast implants using Stratasys’ P3 bioprinter and CollPlant’s bio-inks derived from collagen. The implants are designed to replace silicone implants by regenerating breast tissue without eliciting an immune response.
Stratasys CEO Yoav Zeif said the partnership with CollPlant “will enable us to accelerate the industrialization of bioprinting for regenerative medicine, and we look forward to the successful commercialization of CollPlant’s novel regenerative breast implants and beyond.”
CollPlant CEO Yehiel Tal said the company is “excited to collaborate on this transformative initiative.”
“We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer,” he added.
In January, CollPlant completed an animal trial for the 3D bio-printed breast implants, and the objectives were fully-achieved. The study, not yet clinical, showed progressive stages of tissue regeneration after three months.
In February, Stratasys released TrueDent, a dental resin cleared by the FDA, which will be used for the 3D printing of dental parts, including dentures and temporary crowns, and bridges.